Business
FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on rare diseases, today announced that results from its Phase 2 FIGHT DMD clinical trial were selected for a late-breaking presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas. The trial demonstrated significant cardiac benefits for patients with Duchenne muscular dystrophy (DMD), potentially addressing the leading cause of death in th
About this update from Cumberland Pharmaceuticals Inc.
[{"type":"text","content":"Ifetroban demonstrated significant 5.4% improvement in cardiac function ","length":71,"tagName":"p","attribs":{}},{"type":"text","content":"NASHVILLE, Tenn., March 19, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on rare diseases, today announced that results from its Phase 2 FIGHT DMD clinical trial were selected for a late-breaking presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas. The trial demonstrated significant cardiac benefits for patients with Duchenne muscular dystrophy (DMD), potentially addressing the leading cause of death in this devastating disease.","length":581,"tagName":"p"},{"type":"image","alt":"Cumberland Pharmaceuticals Logo (PRNewsFoto/Cumberland Pharmaceuticals Inc.)","displaySize":"","headline":null,"caption":"Cumberland Pharmaceuticals Logo (PRNewsFoto/Cumberland Pharmaceuticals Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":85,"url":"https://media.zenfs.com/en/prnewswire.com/3afebe83ec3d4bc266a4bcc9278af913"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/W65H8Am_Z_mSA2sDK0ostg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE1MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/3afebe83ec3d4bc266a4bcc9278af913","width":400,"height":85}},"href":"https://mma.prnewswire.com/media/84325/Cumberland_Pharmaceuticals_logo_new1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The presentation, delivered today by Dr. John Jerry Parent, highlighted the breakthrough findings from Cumberland's study of ifetroban in DMD heart disease. For the abstract presented at the meeting, please see the MDA website. ","length":232,"tagName":"p"},{"type":"text","content":"The Phase 2 FIGHT DMD trial demonstrated that high-dose ifetroban treatment resulted in a 3.3% improvement in left ventricular ejection fraction (LVEF) compared to placebo. When compared with propensity-matched natural history controls, the difference was even more pronounced, with high-dose treatment providing a significant 5.4% overall improvement in LVEF, as control patients experienced a 3.6% decline in LVEF. This improvement in cardiac function could translate to meaningful benefits in quality of life and survival for DMD patients. The complete...